The Medicines Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From The Medicines Company
Certa’s lead candidate has shown promise in a mid-stage trial for the rare but debilitating skin disorder, triggering pivotal development plans to address the high unmet need.
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
- Other Names / Subsidiaries
- Annovation Biopharma, Inc.
- Boxford Subsidiary
- Curacyte Discovery GmbH
- Incline Therapeutics, Inc.
- ProFibrix B.V.
- Rempex Pharmaceuticals, Inc.
- Targanta Therapeutics Corporation
- Tenaxis Medical
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.